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a b s t r a c t
Heparin is a sulfated glycan widely used as anticoagulant in medicine. Mallard Blue (MalB), a small
cationic dye developed in our laboratories, is able to detect heparin in serum and plasma in a dose-
response manner, with performance superior to its direct competitors. However, many aspects of
MalB/heparin binding still remain to be explored which, once solved, may foster the clinical use of MalB.
Among these, the characterization of the energetics that drives the MalB/heparin binding process, the
competition for MalB binding by other polyanions (e.g., negatively-charged surfactant micelles), and the
interaction of MalB with serum proteins are of particular interest. This work ﬁlls this gap by means of a
combination of experimental investigations (UV-visible spectroscopy and isothermal titration calorim-
etry), and computational approaches based on molecular dynamics (MD) simulation techniques. In
combination, the results obtained show that MalB efﬁciently binds to both heparin and SDS, with the
binding being enthalpic in nature; yet, SDS is able to extract MalB from its complex with heparin when
the surfactant is in its self-assembled form, the driving force underlying SDS-induced MalB/heparin de-
complexation being entropic in nature as the two enthalpies of binding effectively cancel each other out.
Once bound to SDS, the dye remains electrostatically bound to the micellar surface and does not
penetrate the micelle palisade layer, as veriﬁed by steered molecular dynamics/umbrella sampling
simulations. Finally, the afﬁnity of MalB for human serum albumin (HSA), the most abundant plasma
protein, is found to be lower than that for heparin, conﬁrming the ability of the dye to work in complex
physiological environments.
1. Introduction
Heparin, a linear polysaccharide consisting of repeating units of
2-O-sulfated iduronic acid and 6-O-sulfated, N-sulfated glucos-
amine (IdoA(2S)-GlcNS(6S), Fig. 1 left) - is one of the most charge-
dense naturally occurring polyanion in biological systems [1].
Heparin has been used as an anticoagulant since 1935 to both treat
and prevent the deep vein thrombosis that can result from large
surgery, blood transfusions, or dialysis. As a result of its clinical
importance, there has been a surge of interest in developing
heparin sensors which can directly detect heparin chains within a
complex biological sample (that is, measure a true concentration)
rather than rely on an activity measurement within plasma or
serum (units of anticoagulant activity). Perhaps the leading strat-
egy has been the development of cationic indicator dyes which can
quickly report on heparin spectroscopically. In this respect, several
molecules such as Azure A [2,3], Alcian Blue [4], Methylene Blue [5],
Heparin Blue and Heparin Orange [6] e which all exhibit UV
response to heparin e have historically been employed. Yet, while
these cationic dyes work well in noncompetitive environments,
many of them lose efﬁciency a) in the presence of other agents (e.g.,
plasma proteins) that directly interfere with their heparin non-
covalent binding and b) as electrolytic competition increases.
In the quest for alternative heparin sensors that can quantita-
tively and reliably perform under physiological conditions, in 2013
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2our group synthesized Mallard Blue (MalB, Fig. 1 right), a thionine-
di-arginine molecule that can be readily obtained via a coupling
reaction between Tri-Boc-protected arginine and thionine acetate
followed by Boc deprotection [7].
In the same study [7], we established that MalB is able to detect
heparin in serum and plasma in a dose-response manner, its su-
perior performance with respect to the direct competitor Azure A,
its heparin speciﬁcity and, likely its most interesting and promising
property, its resistance to high ionic strength (e.g., 150 mM NaCl),
despite the fact that electrostatic forces govern its interaction with
the polyanion. Interestingly, the excellent sensing properties of
MalB under physiologically conditions were the subject of a posi-
tive News and Views article which appeared in Nature Chemistry in
the same year [8].
Under this promising scenario, however, many aspects still
remain to be explored which, once solved, may foster the clinical
use of MalB. Among these, the characterization of the energetics
that drive the MalB/heparin binding process, the competition for
MalB binding by other polyanions (e.g., negatively-charged sur-
factant micelles), and the interaction of MalB with serum proteins
still remain to be performed. This work aims to ﬁll this gap by
means of a combination of experimental investigations, based on
UV-visible spectroscopy and isothermal titration calorimetry (ITC),
and computational approaches, relying on molecular dynamics
(MD) simulation techniques.
Speciﬁcally, since the interaction ofMalBwith heparin has never
been fully characterized so far, either from a spectrometric or from
a thermodynamic point of view, we ﬁrst report and discuss the
spectroscopic and thermodynamic behavior for MalB binding to
heparin and compare them with that obtained for negatively-
charged micelles generated by the self-assembly of a conven-
tional anionic surfactant sodium dodecyl sulfate (SDS). The idea
underlying these experiments is that, given the predictable elec-
trostatic nature of heparin/MalB interaction, highly oppositely-
charged micelles may compete with the polysaccharide and pro-
mote MalB dissociation with subsequent sequestration. Indeed,
micelle-assisted “extraction” of bound ligands from polyanions is a
competitive phenomenon, particularly in the case of DNA (e.g.,
drugs/mutagens DNA de-intercalation). However, the energy cost
for such processes is still not properly understood. Therefore, we
deemed it very interesting to investigate this particular aspect in
case of MalB. These experiments are paralleled by computational
investigations based on steered molecular dynamics [8e12], which
allow us to mimic MalB unbinding from heparin and subsequent
association with SDS micelles at a molecular level.
Next, we present the results of binding thermodynamics of MalB
to the most representative plasma protein, human serum albumin
(HSA), and resort again to atomistic MD simulations in the Mo-
lecular Mechanics/Poisson-Boltzmann framework of theory [see
13e16 and references therein] to identify the molecular de-
terminants underlying its interaction with the heparin sensor.
without further puriﬁcation. Mallard Blue, heparin and human
serum albumin were available from our previous work [7,17e22].
2.1. UV-visible spectroscopy
UV-visible absorbance was measured on a DeNovix DS11-FX
spectrophotometer (DeNovix Inc., Wilmington, DE, USA). All MalB
solutions were incubated at 50 �C for 24 h prior to use and stored in
the dark. For the MalB/heparin binding, solutions of MalB (125 mM)
in 150 mM NaCl and 10 mM Tris HCl were incubated with solutions
of heparin at progressively increasing concentrations in the same
buffer (9, 17, 34, 67.5, 125, 250, 500, and 1000 mM). For MalB/SDS
binding, a series of SDS solutions (0.25, 0.5, 1, 1.5, 2, 3, and 5 mM)
were added to the MalB solutions (125 mM, 150 mM NaCl/10 mM
Tris HCl). The range of SDS concentrations was selected in order to
consider surfactant systems below and above their CMC (1.2 mM,
see below). For SDS/MalB binding in the presence of heparin, a
presoaked MalB/heparin solution was prepared (125 mM MalB/
150 mM heparin, which ensures complete binding [7]) and a series
of SDS solutions (0.25, 0.5, 1, 1.5, 2, 3, 5, and 10mM) were added. All
experiments were carried out at 25 �C and performed in triplicate.
The absorbance at 615 nm was recorded after each addition.
2.2. Isothermal titration calorimetry (ITC)
2.2.1. Binding of MalB to heparin, SDS micelles, and SDS-driven
MalB extraction from heparin
ITC experiments were conducted using MicroCal PEAQ-ITC
calorimeter (Malvern, UK) at 25 �C. The cell volume was 280 mL.
All experiments were conducted in a backward manner, that is, by
step-by-step injections of a constant volume of concentrated hep-
arin or SDS solutions into the calorimetric cell containing buffer
(150 mM NaCl/10 mM Tris HCl, pH 7.4), or buffered solutions of
MalB, respectively. For SDS-driven MalB extraction from heparin
assay, a buffered MalB solution in large excess of heparin (to ensure
complete MalB/heparin binding) in the cell was used instead.
Speciﬁcally, for SDS CMC determination, a constant 1 mL portion of
SDS solution (60 mM) was repeatedly injected (37 times) into the
reaction cell at 150 s intervals. For MalB binding by heparin, a
polyanion solution (2 mM) was injected in 37 portions of 1 mL at
150 s intervals, while theMalB concentration in the calorimeter cell
was 125 mM. For MalB/SDS binding, a 1 mM solution of MalB in the
cell was titrated with 37 portions of 1 mL of a 300 mM SDS solution
at 150 s intervals, such that the concentration of SDS was always
above the CMC, and allowing us to make the assumption that the
micelles remained intact throughout the experiment. For the MalB/
heparin extraction by SDS micelles, the calorimeter cell was ﬁlled
with a pre complexed MalB/heparin solution (1 mM/5 mM), and
titration was performed with a 300 mM solution of SDS (37 por-
tions of 1 mL at intervals of 150 s). All solutions and buffers were
degassed for 30min at room temperature under stirring at 750 rpm
prior to each experiment. After careful washing, the cell was pre-
rinsed with a portion of the buffer, MalB, or MalB/heparin solu-
tions, respectively. Upon ﬁlling the cell and syringe, stirring was
turned on and each systemwas allowed to thermally equilibrate for
30 min. The heat signal resulting from mixing, dilution effects and
liquid frictionwere further conﬁrmed by control experiments (data
not shown); accordingly, they were subtracted from the relevant
data sets to yield the corrected integrated data. All experiments
were run in triplicate.
Fig. 1. Molecular model of the predominant average repeat unit of heparin (left) and of
Mallard Blue (MalB, right). In each structure, the molecules are shown as atom-colored
sticks-and balls (C, gray; O, red; N, blue; S, yellow; H, white). Naþ and Cl� counterions
are portrayed as purple and green spheres, respectively. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
2. Materials and methods
All chemicals were purchased from Sigma Aldrich, and used
32.2.2. Binding of MalB to HSA
For this ITC experiment, the instrument cell was ﬁlled with a
50 mM buffered (150 mM NaCl/10 mM Tris HCl, pH 7.4) solution of
HSA. Titration was performed with a 500 mM buffered solution of
MalB, added in 19 portions of 1 mL, with time intervals of 150 s.
2.3. Molecular simulations
2.3.1. Model building, reﬁnement and simulation details
All simulations discussed in this workwere carried out using the
AMBER16 suite of programs [23], the GAFF force ﬁeld [24] and
performed with the GPU version of pmemd (pmemd.cuda) in
AMBER16 on our MOSE GPU/CPU cluster. AMBER16 is the state of
the art simulation platform universally recognized and adopted for
simulating biological systems and their interactions with soft
matter and small molecules. A SDS micelle (consisting of 60 sur-
factant monomers) was built using the Micelle Maker server [25],
and optimized, following a consolidated procedure for self-
assembly nanostructures [17e22,26e30]. The initial, optimized
structures of heparin, MalB, heparin/MalB complex and ligand-free
human serum albumin (HSA) were taken from our previous work
[7,9,14,17e22].
Docking of MalB to HSA was accomplished by adapting a pro-
cedure described in details in [[13,15,16,31e34] and references
therein]. Brieﬂy, docking experiments were performed with Auto-
dock 4.2/Autodock Tools 1.4.6 [35]. The resulting docked confor-
mations were clustered and visualized; then, only the molecular
conformation satisfying the combined criteria of having the lowest
(i.e., more favorable) Autodock energy and belonging to a highly
populated cluster was selected to carry forward for further
modeling. The MalB/HSA complex obtained from the docking pro-
cedure was further reﬁned in Amber 16 using the quenched mo-
lecular dynamics (QMD) method as previously described [36e38].
The optimized structures of the SDS micelle, heparin/MalB
complex, and MalB/HSA complex were immersed in a box of TIP3P
water molecules [39]. The choice of the TIP3Pmodel is based on the
fact that it is the best compromise between accuracy description of
the water behavior and computational time required; moreover, it
has been speciﬁcally developed and parametrized to simulate hy-
drated environments of biological macromolecules, surfactants and
small organic molecules. The dimensions of each simulation box
were chosen in order to ensure a 1 nm solvation shell around each
solute structure. Suitable amounts of Naþ and Cl� ions required to
achieve solution neutrality and realize a physiological ionic
strength of 0.15 M were added to each system. The resulting hy-
drated structures were then subjected to an initial Steepest Descent
(SD)/Conjugated Gradient (CG) minimizationwith 5.0 kcal/(mol A2)
restraint on the solute (solvent relaxation), followed by another
round of CG minimization without restraints in order to eliminate
all bad contacts between water molecules and each solute.
Next, each minimized structure was subjected to molecular
dynamics (MD) simulations in the canonical (NVT) ensemble.
During these 100 ps of MD, each system was gradually heated and
relaxed to 25 �C. The SHAKE algorithm [40] was applied to all co-
valent bonds involving hydrogen atoms. An integration time step of
2 fs was adopted together with the Langevin thermostat for tem-
perature regulation (collision frequency ¼ 2.0 ps�1) [41]. The ﬁnal
heating step was followed by 50 ns of MD equilibration in the
isochoric/isothermal (NPT) ensemble. Pressure control was exerted
by coupling the system to a Berendsen barostat (pressure relaxation
time 2 ps) [42]. The Particle Mesh Ewald (PME) method [43] was
used to treat long-range electrostatic interactions under periodic
conditions with a direct space cut-off of 10 A. To generate the
starting conﬁguration for steered molecular dynamics simulations
(Section 2.3.2), a frame of the SDS micelle and of the MalB/heparin
complex was extracted from the corresponding equilibrated MD
trajectories. The entire equilibrated MD run of the MalB/HSA
complex was used in the determination of dye/protein free energy
of binding (section 2.3.3).
2.3.2. Steered molecular dynamics (SMD) and umbrella sampling
(US) simulations
The unbinding process of MalB from heparin and the binding
event between MalB and the SDS micelle were simulated using a
combination of steered molecular dynamics (SMD) [9e12] and
umbrella sampling (US) simulations [44]. In the ﬁrst case, the
MalB/heparin complex structure extracted from the corresponding
equilibrated MD simulations was solvated with a TIP3P water [39]
cubic box, and ions and counter ions were added to neutralize the
system and reach the physiological ionic strength (150 mM NaCl).
In the second case, the optimized SDS micelle and a molecule of
MalB were placed in simulation cell at an initial distance of
approximately 5 nm. The resulting system was solvated using the
same solvent system adopted for the MalB/heparin complex. After
each system equilibration (1 ns of NVT/NPT MD simulation), SMD
runs were performed, and were next used to extract the initial
coordinates for umbrella sampling simulations along the unbind-
ing/binding pathway, respectively. A pulling force with a virtual
spring constant of 50 kcal (mol Å2)�1 was imposed on the ligand
center of mass and the center of mass of the SDS micelle/heparin
in the unbinding/binding simulations, and the speed was 5 Å ns�1
based on considerations of sampling accuracy and computational
efﬁciency. The reaction coordinate for the umbrella sampling
simulations, z, is deﬁned as the distance between the MalB center
of mass (COM) and the COM of heparin when pulling MalB out of
the heparin complex, and between the COM of MalB and the COM
of the SDS micelle when pulling MalB towards the SDS micelle.
During both SMD and US simulations, the heparin/SDS micelle
initial structures were retained in their initial conﬁgurations
applying a small constraint force of 5 kcal (mol Å2)�1 on the co-
ordinates of the heavy atoms of heparin for the unbinding simu-
lations, and on the two terminal carbons of each SDS chain in the
binding simulations.
To perform US simulations, MalB position probability distribu-
tions along the reaction coordinate were extracted from the cor-
responding SMD simulations. US method adopts a biased potential
function imposed on the structure generated by the SMD along z,
according to the following equation:
U0(z) ¼ U(z) þ W(z) (1)
Where U(z) is the potential function and W(z) is a quadratic-form
weighting function:
W(z) ¼ K (z e z0)2/2 (2)
In which K is the harmonic force constant and z0 is the harmonic
potential center.
In this work, each path was subdivided in 80 windows (spacing
0.8 Å), enough to push the MalB inside the SDS micelle in the
binding simulation, and to bring the MalB fairly far away from
heparin in the unbinding one. An equilibration time of 1 ns was
adopted for each window, and data collection lasted 4 ns per
window, yielding a total data collection time of 320 ns?. A value of
K ¼ 5 kcal/mol was set to restrain z in all simulations. The
weighted histogram analysis method (WHAM) [45] was used to
unbias simulations and to retrieve the PMF. Errors were estimated
by the bootstrapping analysis implemented in the WHAM package
[46].
42.3.3. Mallard Blue/human serum albumin free energy of binding
calculations
The free energy of binding between MalB and HSAwas obtained
by applying the Molecular Mechanics/Poisson Boltzmann Surface
Area (MM/PBSA) approach [13e16]. This computational technique
employs snapshots taken from MD trajectories to estimate the
average interaction energies based on the solute molecular me-
chanics internal energy and solvation energy (constituting the
enthalpic term), and entropy variation. The solvation term is
calculated solving the Poisson-Boltzmann equation [47] while DGnp
can be obtained via the semi-empirical expression [48]:
DGnp ¼ g � SASA þ b, in which SASA is the solvent accessible
surface area of the molecule, g is the surface tension parameter
(0.00542 kcal/Å2/mol), and b ¼ 0.92 kcal/mol. Finally, the entropic
contribution is calculated via normal mode of harmonic fre-
quencies [49] obtained from a subset of minimized snapshots taken
from the corresponding MD trajectories. For the analysis of the
energy of interaction between HSA and MalB, energy values were
averaged over 200 frames taken during equally spaced time in-
tervals along the last 15 ns of the MD production steps. Normal
mode analysis was carried out on a subset of 15 minimized MD
snapshots evenly extracted from the relevant trajectory time frame
used for energy calculations.
3. Results and discussion
3.1. UV-visible spectroscopy assays
The ﬁrst experiment was carried out to investigate the binding
of MalB to SDS using UV-visible spectroscopy. The insert in Fig. 2A
shows a representative set of the UV-visible spectra of MalB in the
absence and in the presence of increasing concentration of SDS (the
full curve set is shown in Fig. SI1). As already reported in our pre-
vious investigation [7], MalB in 150mMNaCl/10mM Tris HCl buffer
produces an absorption peak at 615 nm; upon addition of SDS, the
maximum absorbance initially decreases and then increases with
increasing surfactant concentration. This non-monotonic behavior
can be better appreciated by plotting the relative change in ab-
sorption intensity (I/I0, where I and I0 are the peak absorption
values in the presence and absence of SDS, respectively), as illus-
trated in Fig. 2A.
We see from this Figure that, for small additions of SDS (i.e.,
[SDS] < CMCSDS), I/I0 attains values lower than 1. This initial
quenching of the MalB UV-visible absorbance intensity can be
attributed to the interaction of MalB molecules with SDS surfactant
in its monomeric form, in agreement with previous literature re-
ports for other cationic dyes, e.g., Nile Blue [50] and phenosafranine
[51]. As [SDS] approaches CMCSDS in the adopted buffer conditions
(CMCSDS¼ 1.02mM in 150 mMNaCl/10 mM Tris HCl, see Fig. SI2), I/
I0 rapidly increases and then levels-off for surfactant concentration
values > 3 mM (Fig. 2A). The substantial increase in the absorption
spectrum intensity of MalB at higher SDS concentrations is indic-
ative of a tighter binding of the dye with SDS micelles driven by
electrostatic forces between the highly negative micellar surface
and the positive charges present on the molecular dye, which
places MalB into a different environment [52e54].
Fig. 2B shows the proﬁle of I/I0 for the interaction between MalB
and heparin. In this case, the initial electrostatic polyanion/MalB
interactions result in a plummet of the MalB UV-visible absorption
intensity, followed by a considerably less pronounced decrease of I/
I0 vs. [Heparin] once all polysaccharide binding sites become
saturated by dye binding (i.e., 125 mM < [Heparin] < 250 mM).
Interestingly, a similar behavior has been reported for Nile Blue
binding to DNA [50,55], suggesting that common mechanisms may
underlie the interactions of different cationic molecules with the
two seemingly different, negatively charged biomacromolecules.
When SDS solutions are added to a pre-formed MalB/heparin
complex, the UV-visible spectra reported in Fig. 2C are obtained.
The initially ﬂat curve of I/I0 as a function of [SDS] rapidly increases
for [SDS] � CMCSDS and ultimately plateaus for [SDS] > 2.5 mM. In
this last surfactant concentration range, the absorption intensity
values correspond to those observed for MalB in the pure SDS
micellar environment, strongly supporting the notion that the dye,
no longer bound to heparin, has been complexed by the surfactant
self-assembled spherical micelles.1
3.2. Isothermal titration calorimetry (ITC) assays
To experimentally quantify - for the ﬁrst time - the binding
thermodynamics between MalB and heparin, to conﬁrm the spec-
troscopic evidences of MalB/SDS micelle interactions, and to verify
the ability of SDS micelles to extract MalB from heparin, we
resorted to ITC measurements, as shown in Fig. 3.
The binding of MalB to heparin (Fig. 3A) is strongly exothermic
(DHb ¼ �9.36 ± 0.24 kcal/mol), while a small, negative entropy
change opposes dye/polyanion interaction (TDSb¼�1.47 kcal/mol).
Accordingly, MalB/heparin complex formation is thermodynami-
cally favored, with a free energy of binding DGb value ofe 7.89 kcal/
mol (see Fig. 4A). The large, negative enthalpy variation observed in
Fig. 2. Relative change in UV-visible absorbance intensity (I/I0) of (A) MalB as a function of SDS concentration, (B) MalB as a function of heparin concentration, and (C) heparin/MalB
complex as a function of SDS concentration in 10 mM Tris HCl and physiological ionic strength (150 mM NaCl). In all experiments, [MalB] ¼ 125 mM. The corresponding absorbance
spectra is shown in the relative Figure insets. For clarity, only a representative set of the corresponding absorbance spectra is shown in the inset of panel A (see Fig. SI1 for the full
curve set).
1 It should be noted that the I/I0 value appears larger in Fig. 2C than 2A because
the starting point of the experiment, and hence the value of I0, is different. In Fig. 2A
the starting point I0 value corresponds to uncomplexed MalB, whereas in Fig. 2B,
the starting point I0 corresponds to MalB bound to heparin.
5MalB/heparin complex formation is comparable to that observed
for, e.g., small molecule/DNA or drug/protein binding
[9e22,26e34], and can be ascribed to the formation of a network of
stabilizing non-speciﬁc intermolecular interactions (i.e., electro-
static, hydrogen bonds, salt bridges) between the two molecular
entities. The small and unfavorable entropic term is also quite
characteristic of these processes, since macromolecule/ligand hy-
drophobic interactions and water/ion release into the bulk cannot
compensate for the loss in degree of freedom of experienced by the
dye/polyanion upon binding.
The interaction of SDS micelles with MalB (Fig. 3B) is also
enthalpically driven (DHb ¼ �9.06 ± 0.19 kcal/mol) and, as for
MalB/heparin binding, is characterized by a small entropic penalty
(TDSb ¼ - 1.64 kcal/mol), resulting in an overall favorable binding
free energy DGb of �7.42 kcal/mol (Fig. 4B). The fact that the MalB/
SDS has a substantial enthalpic nature supports the fact that hy-
drophobic interactions contribute only in minimal part to this
speciﬁc dye/micelle binding, and electrostatic forces play the
leading role. This, in turn, suggests that, once bound, MalB prefers
to reside in the micellar outer Stern layer rather than locating itself
into the palisade layer or deep inside the micellar core (see Section
3.3).
Finally, ITC measurements reveal that, when SDS micelles are
added to a MalB/heparin complex solution, the thermodynamic
nature of the underlying process is opposite with respect to that
described above (Fig. 3C). Indeed, while an almost negligible,
endothermic contribution is measured (DHb ¼ þ 0.23 ± 0.04 kcal/
mol), the driving force for MalB extraction from heparin by SDS
micelles results from the strong, positive entropic variation
(TDSb ¼ þ 6.25 kcal/mol), which ultimately determines the overall
negative value of the free energy (DGb ¼ �6.02 kcal/mol) (see
Fig. 4C). The increase in system entropy can be attributed to several,
concomitant factors, including i) an increase in degrees of freedom
of heparin after MalB complexation, ii) the disruption of hydrogen
bonds and electrostatic interactions between water molecules/
counterions and the micellar surface upon MalB binding, and iii)
their subsequent release into the bulk solvent.
In order to model the process of MalB extraction from heparin
by the anionic surfactant micelles the following two-step model
can be assumed:
ðMalB=HeparinÞhydr# ðMalBÞhydr þ ðHeparinÞhydr (3)
ðSDS micellesÞhydr þ ðMalBÞhydr# ðMalB=SDS micellesÞhydr (4)
in which all different species are considered in their hydrated form
in the relevant buffer. The approach is obviously a rough simpliﬁ-
cation of reality, as i) it assumes that Eqs. (3) and (4) represent
independent events and ii) additional steps associated with these
two major events either do not contribute signiﬁcantly to the
overall process or their effects are accounted for by the equilibrium
thermodynamic parameters. Under this hypothesis, and with the
further assumption that each binding process is reversible, the
unbinding of MalB from heparin (i.e., Eq. (3)) should then be
characterized by a positive enthalpic contribution of þ9.36 kcal/
mol (i.e., -DHb in Figs. 3A and 4A). Since Eq. (4) represents the direct
titration of MalB with SDS micelles, the enthalpic term corresponds
to DHb ¼ �9.06 kcal/mol (Figs. 3B and 4B). Thus, for the extraction
of MalB from its heparin complex by SDS micelles an endothermic
contribution of þ0.30 kcal/mol (viz, þ9.36e9.06 kcal/mol) is esti-
mated, which matches the experimental þ0.23 kcal/mol directly
measured by ITC, as discussed above (Fig. 4C). The nice agreement
Fig. 3. Representative integrated ITC proﬁles for titration of (A) MalB with heparin, (B) MalB with SDS, and (C) MalB/heparin complex with SDS in 10 mM Tris HCl and physiological
ionic strength (150 mM NaCl). T ¼ 25 �C. The solid red lines are data ﬁtting with a sigmoidal function. The inserts in each panel show the corresponding ITC raw data. All ex-
periments were run in triplicate. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. ITC-derived thermodynamic parameters (DHb, full color; TDSb, square pattern; DGb, diagonal line pattern) for (A) MalB binding with heparin, (B) MalB binding with SDS, and
(C) extraction of MalB from the MalB/heparin complex with SDS. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
6between the results obtained from the model of SDS-driven MalB
decomplexation from heparin and the relevant experimental data,
means we can conclude that the underlying assumption that two
processes described by Eqs. (3) and (4) indeed take place in suc-
cessive steps.
3.3. Steered molecular dynamics (SMD) and umbrella sampling
(US) of MalB/SDS micelle binding
To obtain a molecular view of the ITC data discussed in Section
3.2, we performed computer-based simulations by using SMD and
US simulations. In our case, SMD is used ﬁrst to pull out MalB from
heparin (see Supplementary Material Movie1) and then to drive its
binding onto a SDS micelle (Supplementary Material Movie2), by
applying a guiding potential along a reaction coordinate z, and is
subsequently employed to generate the initial coordinate for the
umbrella sampling computations. Upon US simulations to enhance
extensive sampling along the reaction coordinate, the potential of
mean force (PMF) of the binding/unbinding process can be
constructed.
Supplementary video related to this article can be found at
https://doi.org/10.1016/j.ﬂuid.2017.11.005.
Fig. 5A illustrates the PMF proﬁle as a function of the reaction
coordinate z for the unbinding process of MalB from heparin. As
seen in this Figure, the PMF continually increases as the pulled
MalB transits from the bound to the free state, although some
bumpy features are visible along the pathway. These might be
related to the fact that the 5 positive charges on MalB are pro-
gressively detached from the polyanion and become solvated by
watermolecules and neutralizing counterions. The total free energy
difference between the heparin bound and unbound state of MalB
is 8.10 kcal/mol, in good agreement with the corresponding free
energy of binding measured by ITC (�7.89 kcal/mol, Fig. 4A).
Fig. 5B displays the PMF (z) behavior for the binding of MalB to
the SDS micelle. This Figure shows that the corresponding free
energy minimum is located on the micellar surface, at a distance of
~1.8 nm from the center of its core. As z is further decreased, the
PMF increases steadily. This strongly supports the hypothesis
formulated in Section 3.2, according to which, once bound, the
highly positively-charged MalB molecule does not penetrate the
palisade layer but remains anchored at the oppositely-charged
micellar periphery by virtue of strong, stabilizing electrostatic in-
teractions. The ultimate evidence of surface binding of MalB onto
the micellar surface is given by the Dynamic Light Scattering (DLS)
experiments (see Supporting Information). According to DLS, SDS
assembles in spherical micelles with a hydrodynamic diameter of
~4 nm (see insert in ﬁgure SI3), characterized by a zeta potential
of �63.2 ± 3.1 mV. Upon MalB interaction, the average hydrody-
namic diameter is equal to ~4.8 nm (see ﬁgure SI3) with a zeta-
potential of �52.4 ± 3.7 mV, supporting the fact that SDS mi-
celles/MalB binding takes place at the SDS micellar surface. Finally,
the computed free energy changes associated with the MalB/SDS
binding process, i.e., �7.96 kcal/mol, nicely matches the corre-
sponding ITC-derived value of �7.42 kcal/mol (Fig. 4B).
3.4. Binding thermodynamics of MalB to HSA
One of the most important results previously reported for MalB
as a heparin sensor is that, despite the fact that electrostatics
should govern the interaction between the dye and the polyanion,
the former is able to recognize heparin even in the presence of high
ionic strength, and shows a quantitative linear dose-response
behavior in serum [7]. Human serum albumin is the most abun-
dant (>50%) protein in blood plasma and serves as a depot protein
and transport protein for numerous endogenous and exogenous
compounds. HSA is also the main factor in contributing to the
colloid osmotic pressure of the blood and has been suggested as a
possible source of amino acids for various tissues. Indubitably, al-
bumin is the most multifunctional transport protein and plays an
important role in the transport and deposition of a variety of
endogenous and exogenous substances in blood [56]. For these
reasons, HSA has been considered as a simpliﬁedmodel in studying
interaction and binding of drugs and small molecules with plasma
proteins.
Under this perspective, we decided to quantify for the ﬁrst time
the interaction of MalB with HSA. To this purpose, we resorted
again to a combination of experimental and computational
methods. Fig. 6A reports the ITC results of the MalB/HSA binding,
while panel B of the same Figure shows the comparison between
the main dye/protein thermodynamic parameters as derived from
ITC and MM/PBSA-based molecular dynamics simulations.
Several considerations can be drawn from the analysis of the
data reported in Fig. 6. First, MalB is endowed with a substantially
lower experimental afﬁnity for HSA (DGb ¼ �5.99 kcal/mol) than
for heparin (DGb ¼ �7.89 kcal/mol) or SDS (DGb ¼ �7.42 kcal/mol)
(see Fig. 4). The enthalpic change upon MalB/HSA complex
Fig. 5. PMF proﬁle along the reaction coordinate z for the process of (A) unbinding of MalB from heparin and (B) binding of MalB to a SDS micelle.
7formation is favorable (�7.05 ± 0.12 kcal/mol) whereas the entropy
change opposes binding (�1.06 kcal/mol) (Fig. 6B). The conforma-
tional entropy change is commonly unfavorable in protein-ligand
binding event, as the binding process involves the loss of conﬁgu-
rational degrees of freedom for both the drug molecule and the
protein. However, the entropic penalty paid by the small dye upon
protein binding is largely compensated by the corresponding
enthalpic gain (Fig. 6B), thereby conﬁrming the enthalpic-driven
nature of the binding mechanism of MalB to human serum albu-
min. From the computational standpoint, MalB docking onto HSA
(Fig. 7, left panel) followed by free energy of binding scoring in the
framework of the MM/PBSA methodology results in a calculated
DGb,comp value in excellent agreement (�5.63 kcal/mol) with the
corresponding ITC-derived experimental data (�5.99 kcal/mol), as
illustrated in Fig. 6B. The enthalpic nature of MalB/HSA is conﬁrmed
computationally (�13.82 kcal/mol), as is the unfavorable contri-
bution from entropy variation upon binding (�8.19 kcal/mol). It is
important to observe here that both DHb and TDSb are normally
overestimated inMM/PBSA calculations [37], as in the present case;
yet, a parallel shift is generally observed between experimental and
computed DH and -TDS so that, ultimately, their difference is
indeed close to the relevant experimental value. The analysis of the
MD trajectory for the MalB/HSA complex shows that the dye is
engaged in two permanent salt bridges, involving the negatively
charged side chains of residues Glu379 and Glu593 on the protein
side and one guanidinic and one tertiary amines of the dye,
respectively (Fig. 7, right panel). The intermolecular complex is
further stabilized by two hydrogen bonds that, in a symmetrical
fashion, link the second guanidinic and tertiary amines to the side
chains of Asn383 and Gln394. Finally, residues Leu384, Leu391, and
Ala403 contribute favorable hydrophobic interactions to dye/pro-
tein binding (Fig. 7, right panel).
In aggregate, these data quantitatively support our previous
evidence [7], according to which MalB can overcome one of the
major challenges for heparin sensors (i.e., working in complex
biological ﬂuids), ultimately making it superior to some other
approaches.
4. Conclusions
Heparin, one of the most negatively charged biopolymers, plays
a critical role in the regulation of blood coagulation, cell growth,
and immune response. Moreover, overdose of heparin frequently
induced severe side effects such as hemorrhage, thrombocytopenia,
and osteoporosis. Thus, the selective and sensitive detection of
heparin, is of great importance in general medicine and clinical
settings. In recent years, our group has developed Mallard Blue
(MalB) [7], a new heparin-binding dye that binds heparin in highly
competitive media, including water with high levels of competitive
electrolyte, buffered aqueous solution and human serum, and
simply reports on heparin levels by a signiﬁcant change in its UV-
visible spectroscopic proﬁle. However, several aspects remain to
be explored about the interaction of MalB with its target polyanion,
and their unveiling will undoubtedly inﬂuence how MalB will be
eventually used in biomedical and pharmacological contexts.
In this work, we investigated some of these unexplored issues,
namely the thermodynamics of binding between MalB and hepa-
rin, and the eventual negative interference by the most abundant
plasma proteins, namely human serum albumin (HSA), in theMalB/
heparin complex formation. Also, in analogy with what is observed
for, e.g., DNA and small intercalating molecules, we deemed it
interesting to study the competition for MalB binding by other
polyanions, such negatively-charged sodium dodecyl sulfate (SDS)
micelles. To this purpose, we adopted an integrated approach based
on a combination of experimental and computational technique.
The results obtained from the application of UV-visible spec-
troscopy methods allowed us to establish that, in a common buffer
system (150 mM NaCl/10 mM Tris HCl), MalB efﬁciently binds to
both heparin and SDS; yet, SDS is able to extract MalB from its
complex with heparin when the surfactant is in its self-assembled
Fig. 6. (A) Integrated ITC proﬁles for MalB binding with HSAwith in 10 mM Tris HCl and physiological ionic strength (150 mM NaCl). T ¼ 25 �C. The solid red line is data ﬁtting with
a one-set-of-sites model. The insert in panel A shows the corresponding ITC raw data. Experiments were run in triplicate. (B) Comparison of ITC-derived (colored bars) and in silico
predicted (white bars) thermodynamic parameters for MalB binding with HSA. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
Fig. 7. (Left) Overall space ﬁlling representation of the HSA molecular surface (light
blue) and MalB (gray spheres) docked into the protein binding site. (Right) Details of
MalB in the HSA binding pocket. The protein secondary structure is portrayed in a light
blue-ribbon style, while MalB is shown as atom-colored sticks-and-balls (C, gray; N,
blue; O, red; S, yellow). The side chains of the HSA residues mainly involved in MalB
binding are shown as colored sticks, colored according to the underlying interactions
(salt bridges, sea green; hydrogen bonds, sandy brown; hydrophobic interactions,
ﬁrebrick). Hydrogen atoms, counterions, and water molecules are omitted for clarity.
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
8form (Fig. 2). Accordingly, in this paper we demonstrate, for the ﬁrst 
time, that small, positively charged molecules bound to heparin, 
the most negatively charged polyanion existing in nature, can be 
“sequestrated” by anionic nanomicelles in a way that utterly re-
sembles that seen for DNA. Moreover, given the fundamental 
electrostatic nature of MalB/SDS interactions, once bound the dye 
remains anchored to the micellar surface and does not penetrate 
into the micelle palisade layer, as further conﬁrmed by computa-
tional results. Indeed, the minimum of the potential of mean force 
for MalB/SDS binding is located at a distance matching the radius of 
the surfactant micelle (1.80 nm), and further pulling of MalB to-
wards the center of the micelle results in a steep increase of the free 
energy (Fig. 5). UV-vis results are supported by isothermal titration 
calorimetry (ITC) measurements, according to which heparin and 
SDS have similar afﬁnity for the dye, and in both cases favorable 
enthalpy variations drive the underlying processes (Fig. 4). On the 
other hand, the “extraction” of MalB from heparin by SDS micelles 
is thermodynamically feasible since the major driving force of the 
process is purely entropic in nature, with the enthalpies of binding 
to each of these polyanions effectively canceling one another out. 
Finally, the investigation of the interaction between MalB and hu-
man serum albumin (HSA) reveals that the dye is endowed with 
substantially less afﬁnity for the most abundant plasma proteins 
compared with its afﬁnity for heparin (Fig. 6), conﬁrming the ability 
of this heparin dye to work in complex physiological environments.
Acknowledgments
The work has been ﬁnancially supported by the Italian Associ-
ation for Cancer Research (AIRC, IG 2015 ID.17413 to SP).
References
[1] D.A. Lane, U. Lindhal (Eds.), Heparin: Chemical and Biological Properties,
Clinical Applications, CRC Press, Boca Raton, FL, 1989.
[2] M.D. Klein, R.A. Drongowski, R.J. Linhardt, R.S. Langer, A colorimetric assay for
chemical heparin in plasma, Anal. Biochem. 124 (1982) 59e64.
[3] Q.C. Jiao, Q. Liu, Mechanism of interference and Azure A response in the
heparin assay, Anal. Lett. 31 (1998) 1311e1323.
[4] S.B. Frazier, K.A. Roodhouse, D.E. Hourcade, L. Zhang, The quantiﬁcation of
glycosaminoglycans: a comparison of HPLC, carbazole, and Alcian Blue
methods, Open Glycosci. 1 (2008) 31e39.
[5] Q.C. Jiao, Q. Liu, C. Sun, H. He, Investigation on the binding site in heparin by
spectrophotometry, Talanta 48 (1999) 1095e1101.
[6] S. Wang, Y.T. Chang, Discovery of heparin chemosensors through diversity
oriented ﬂuorescence library approach, Chem. Commun. 14 (2008)
1173e1175.
[7] S.M. Bromﬁeld, A. Barnard, P. Posocco, M. Fermeglia, S. Pricl, D.K. Smith,
Mallard Blue: a high-afﬁnity selective heparin sensor that operates in highly
competitive media, J. Am. Chem. Soc. 135 (2013) 2911e2914.
[8] Z. Shriver, R. Sasisekharan, Blue-chip binding, Nat. Chem. 5 (2013) 644e646.
[9] E. Laurini, D. Marson, P. Posocco, M. Fermeglia, S. Pricl, Structure and binding
thermodynamics of viologen-phosphorous dendrimers to human serum al-
bumin: a combined computational/experimental investigation, Fluid Phase
Equilib. 422 (2016) 18e31.
[10] D. Marson, E. Laurini, P. Posocco, M. Fermeglia, S. Pricl, Cationic carbosilane
dendrimers and oligonucleotide binding: an energetic affair, Nanoscale 7
(2015) 3876e3887.
[11] S. Pricl, B. Cortelazzi, V. Dal Col, D. Marson, E. Laurini, M. Fermeglia, L. Licitra,
S. Pilotti, P. Bossi, F. Perrone, Smoothened (SMO) receptor mutations dictate
resistance to vismodegib in basal cell carcinoma, Mol. Oncol. 9 (2015)
389e397.
[12] F. Bozzi, E. Conca, E. Laurini, P. Posocco, A. Lo Sardo, G. Jocoll�e, R. Sanﬁlippo,
A. Gronchi, F. Perrone, E. Tamborini, G. Pelosi, M.A. Pierotti, R. Maestro, S. Pricl,
S. Pilotti, In vitro and in silico studies of MDM2/MDMX isoforms predict
Nutlin-3A sensitivity in well/de-differentiated liposarcomas, Lab. Invest. 93
(2013) 1232e1240.
[13] D. Genini, L. Brambilla, E. Laurini, J. Merulla, G. Civenni, S. Pandit,
R. D'Antuono, L. Perez, D.E. Levy, S. Pricl, G.M. Carbone, C.V. Catapano, Mito-
chondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor
leads to metabolic synthetic lethality in cancer cells, Proc. Natl. Acad. Sci. U. S.
A. 2017 114 (2017) E4924eE4933.
[14] Z. Beiranvand, F. Bani, A. Kakanejadifard, E. Laurini, M. Fermeglia, S. Pricl,
M. Adeli, Anticancer drug delivery systems based on speciﬁc interactions
between albumin and polyglycerol, RSC Adv. 6 (2016) 11266e11277.
[15] D.L. Gibbons, S. Pricl, P. Posocco, E. Laurini, M. Fermeglia, H. Sun, M. Talpaz,
N.J. Donato, A. Quint�as-Cardama, Molecular dynamics reveal BCR-ABL1 poly-
mutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase in-
hibitor therapy, Proc. Natl. Acad. Sci. U. S. A. 111 (2014) 3550e3555.
[16] M.A. Pierotti, E. Tamborini, T. Negri, S. Pricl, S. Pilotti, Targeted therapy in
GIST: in silico modeling for prediction of resistance, Nat. Rev. Clin. Oncol. 8
(2011) 161e170.
[17] A.C. Rodrigo, S.M. Bromﬁeld, E. Laurini, P. Posocco, S. Pricl, D.K. Smith,
Morphological control of self-assembled multivalent (SAMul) heparin binding
in highly competitive media, Chem. Commun. 53 (2017) 6335e6338.
[18] V.M.P. Vieira, V. Liljestr€om, P. Posocco, E. Laurini, S. Pricl, M.A. Kostiainen,
D.K. Smith, Emergence of highly-ordered hierarchical nanoscale aggregates on
electrostatic binding of self-assembled multivalent (SAMul) cationic micelles
with polyanionic heparin, J. Mater. Chem. B 5 (2017) 341e347.
[19] C.W. Chan, E. Laurini, P. Posocco, S. Pricl, D.K. Smith, Chiral recognition at self-
assembled multivalent (SAMul) nanoscale interfaces e enantioselectivity in
polyanion binding, Chem. Commun. 52 (2016) 10540e10543.
[20] L.E. Fechner, B. Albanyan, V.M.P. Vieira, E. Laurini, P. Posocco, S. Pricl,
D.K. Smith, Electrostatic binding of polyanions using self-assembled multi-
valent (SAMul) ligand displays-structure-activity effects on DNA/heparin
binding, Chem. Sci. 7 (2016) 4653e4659.
[21] S.M. Bromﬁeld, P. Posocco, C.W. Chan, M. Calderon, S.E. Guimond,
J.E. Turnbull, S. Pricl, D.K. Smith, Nanoscale self-assembled multivalent
(SAMul) heparin binders in highly competitive, biologically relevant, aqueous
media, Chem. Sci. 5 (2014) 1484e1492.
[22] S.M. Bromﬁeld, P. Posocco, M. Fermeglia, S. Pricl, J. Rodríguez-L�opez,
D.K. Smith, A simple new competition assay for heparin binding in serum
applied to multivalent PAMAM dendrimers, Chem. Commun. 49 (2013)
4830e4832.
[23] D.A. Case, R.M. Betz, W. Botello-Smith, D.S. Cerutti, T.E. Cheatham III,
T.A. Darden, R.E. Duke, T.J. Giese, H. Gohlke, A.W. Goetz, N. Homeyer, S. Izadi,
P. Janowski, et al., AMBER 2016, University of California, San Francisco (CA,
USA), 2016.
[24] J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, D.A. Case, Development and
testing of a general amber force ﬁeld, J. Comput. Chem. 25 (2004) 1157e1174.
[25] www.micelle.icm.uu.se.
[26] B. Albanyan, E. Laurini, P. Posocco, S. Pricl, D.K. Smith, Self-assembled multi-
valent (SAMul) polyanion binding-impact of hydrophobic modiﬁcations in the
micellar core on DNA and heparin binding at the peripheral cationic ligands,
Chem. Eur. J. 23 (2017) 6391e6397.
[27] C. Chen, P. Posocco, X. Liu, Q. Cheng, E. Laurini, J. Zhou, C. Liu, Y. Wang, J. Tang,
V. Dal Col, T. Yu, S. Giorgio, M. Fermeglia, F. Qu, Z. Liang, J.J. Rossi, M. Liu,
P. Rocchi, S. Pricl, L. Peng, Mastering dendrimer self-assembly for efﬁcient
siRNA delivery: from conceptual design to in vivo efﬁcient gene silencing,
Small 12 (2016) 3667e3676.
[28] T. Wei, C. Chen, J. Liu, C. Liu, P. Posocco, X. Liu, Q. Cheng, S. Huo, Z. Liang,
M. Fermeglia, S. Pricl, X.J. Liang, P. Rocchi, L. Peng, Anticancer drug nano-
micelles formed by self-assembling amphiphilic dendrimer to combat cancer
drug resistance, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) 2978e2983.
[29] X. Liu, J. Zhou, T. Yu, C. Chen, Q. Cheng, K. Sengupta, Y. Huang, H. Li, C. Liu,
Y. Wang, P. Posocco, M. Wang, Q. Cui, S. Giorgio, M. Fermeglia, F. Qu, S. Pricl,
Y. Shi, Z. Liang, P. Rocchi, J.J. Rossi, L. Peng, Adaptive amphiphilic dendrimer-
based nanoassemblies as robust and versatile siRNA delivery systems, Angew.
Chem. Int. Ed. Engl. 53 (2014) 11822e11827.
[30] A. Barnard, P. Posocco, S. Pricl, M. Calderon, R. Haag, M.E. Hwang, V.W. Shum,
D.W. Pack, D.K. Smith, Degradable self-assembling dendrons for gene de-
livery: experimental and theoretical insights into the barriers to cellular up-
take, J. Am. Chem. Soc. 133 (2011) 20288e20300.
[31] V. Perfetti, E. Laurini, S. Auli�c, M. Fermeglia, R. Riboni, M. Lucioni, E. Dallera,
S. Delfanti, L. Pugliese, F.S. Latteri, A. Pietrabissa, S. Pricl, Molecular and
functional characterization of a new 30 end KIT juxtamembrane deletion in a
duodenal GIST treated with neoadjuvant Imatinib, Oncotarget 8 (2017)
56158e56167.
[32] A.K. Kokornaczyk, D. Schepmann, J. Yamaguchi, K. Itami, E. Laurini,
M. Fermeglia, S. Pricl, B. Wünsch, Thiazole-based s1 receptor ligands: di-
versity by late-stage C-H arylation of thiazoles, structure-afﬁnity and selec-
tivity relationships, and molecular interactions, ChemMedChem 12 (2017)
1070e1080.
[33] D. Zampieri, L. Vio, M. Fermeglia, S. Pricl, B. Wünsch, D. Schepmann,
M. Romano, M.G. Mamolo, E. Laurini, Computer-assisted design, synthesis,
binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-
heterocyclic sigma 1 ligands, Eur. J. Med. Chem. 121 (2016) 712e726.
[34] A. Carta, I. Briguglio, S. Piras, P. Corona, R. Ibba, E. Laurini, M. Fermeglia,
S. Pricl, N. Desideri, E.M. Atzori, P. La Colla, G. Collu, I. Delogu, R. Loddo,
A combined in silico/in vitro approach unveils common molecular re-
quirements for efﬁcient BVDV RdRp binding of linear aromatic N-polycyclic
systems, Eur. J. Med. Chem. 117 (2016) 321e334.
[35] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell,
9A.J. Olson, AutoDock4 and AutoDockTools4: automated docking with selective
receptor ﬂexibility, J. Comput. Chem. 30 (2009) 2785e2791.
[36] C. Meyer, D. Schepmann, S. Yanagisawa, J. Yamaguchi, V. Dal Col, E. Laurini,
K. Itami, S. Pricl, B. Wünsch, Pd-catalyzed direct C-H bond functionalization of
spirocyclic sigma-1 ligands: generation of a pharmacophore model and
analysis of reverse binding mode by docking into a 3D homology model of the
sigma-1 receptor, J. Med. Chem. 55 (2012) 8047e8065.
[37] D. Rossi, A. Pedrali, R. Gaggeri, A. Marra, L. Pignataro, E. Laurini, V. Dal Col,
E. Fermeglia, S. Pricl, D. Schepmann, B. Wünsch, M. Peviani, D. Curti, S. Collina,
Chemical, pharmacological, and in vitro metabolic stability studies on enan-
tiomerically pure RC-33 compounds: promising neuroprotective agents acting
as s1 receptor agonists, ChemMedChem 8 (2013) 1514e1527.
[38] E. Laurini, D. Harel, D. Marson, D. Schepmann, T. Schmidt, S. Pricl, B. Wünsch,
Identiﬁcation, pharmacological evaluation and binding mode analysis of novel
chromene and chromane based s1 receptor ligands, Eur. J. Med. Chem. 83
(2014) 526e533.
[39] W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey, M.L. Klein, Com-
parison of simple potential functions for simulating liquid water, J. Chem.
Phys. 79 (1983) 926e935.
[40] J.P. Ryckaert, G. Ciccotti, H.J.C. Berendsen, Numerical integration of the car-
tesian equations of motion of a system with constraints: molecular dynamics
of n-alkanes, J. Comput. Phys. 23 (1977) 327e341.
[41] X. Wu, B.R. Brooks, Self-guided Langevin dynamics simulation method, Chem.
Phys. Lett. 381 (2003) 512e518.
[42] H.J.C. Berendsen, J.P.M. Postma, W.F. van Gunsteren, A. DiNola, J.R. Haak,
Molecular dynamics with coupling to an external bath, J. Chem. Phys. 81
(1984) 3684e3690.
[43] T. Darden, D. York, L. Pedersen, Particle mesh Ewald: an N log(N) method for
Ewald sums in large systems, J. Chem. Phys. 98 (1993) 10089e10092.
[44] J. K€astner, Umbrella sampling, WIREs 1 (2011) 932e942.
[45] S. Kumar, D. Bouzida, R.H. Swendsen, P.A. Kollman, J.M. Rosenberg, The
weighted histogram analysis method for free-energy calculations on bio-
molecules. I. The method, J. Comput. Chem. 13 (1992) 1011e1021.
[46] http://membrane.urmc.rochester.edu/content/wham.
[47] M.K. Gilson, K.A. Sharp, B.H. Honig, Calculating the electrostatic potential of
molecules in solution e method and error assessment, J. Comput. Chem. 9
(1988) 327e335.
[48] D. Sitkoff, K.A. Sharp, B.H. Honig, Accurate calculation of hydration free en-
ergies using macroscopic solvent models, J. Phys. Chem. 98 (1994)
1978e1988.
[49] I. Andricioaei, M. Karplus, On the calculation of entropy from covariance
matrices of the atomic ﬂuctuations, J. Chem. Phys. 115 (2001) 6289e6292.
[50] R.K. Mitra, S.S. Sinha, S.K. Pal, Interactions of Nile Blue with micelles, reverse
micelles and a genomic DNA, J. Fluoresc. 18 (2008) 423e432.
[51] A. Patra, S. Hazra, G.S. Kumar, R.K. Mitra, Entropy contribution toward micelle-
driven deintercalation of drugdNA complex, J. Phys. Chem. B 118 (2014)
901e908.
[52] P. Das, A. Chakrabarty, A. Mallick, N. Chattopadhyay, Photophysics of a
cationic biological photosensitizer in anionic micellar environments: com-
bined effect of polarity and rigidity, J. Phys. Chem. B 111 (2007) 11169e11176.
[53] M. Afzal, S. Ghosh, S. Das, N. Chattopadhyay, Endogenous activation-induced
delivery of a bioactive photosensitizer from a micellar carrier to natural DNA,
J. Phys. Chem. B 120 (2016) 11492e11501.
[54] S. Chatterjee, G.S. Kumar, Visualization of stepwise drug-micelle aggregate
formation and correlation with spectroscopic and calorimetric results, J. Phys.
Chem. B 120 (2016) 11751e11760.
[55] R.K. Mitra, S.S. Sinha, S. Maiti, S.K. Pal, Sequence dependent ultrafast electron
transfer of Nile Blue in oligonucleotides, J. Fluoresc. 19 (2009) 353e361.
[56] G. Fanali, A. di Masi, V. Trezza, M. Marino, M. Fasano, P. Ascenzi, Human serum
albumin: from bench to bedside, Mol. Asp. Med. 33 (2012) 209e290.
